SEC Form 4 · accession 0001225208-17-010625
Edwards Lifesciences Corp · EW
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Patrick B Verguet
Officer — CVP, Europe
Period of report
May 31, 2017
Accepted (ET)
May 31, 2017 · 6:49 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001099800
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | May 31, 2017 | M | 10,000 | $44.615 | A | 139,137 | D | |
| Common StockF2,F1 | May 31, 2017 | S | 10,000 | $114.876 | D | 129,137 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Acquire)F1 | $44.615 | May 31, 2017 | M | 10,000 | D | May 12, 2012 | May 11, 2018 | Common Stock | 10,000 | 38,800 | D |
Explanation of responses
- F1This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the reporting person.
- F2This transaction was executed in multiple trades at prices ranging from $114.7519 to $115.00. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected.